Results 91 to 100 of about 49,423 (253)
Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 6, Page 1108-1118, June 2025.ABSTRACT Ritlecitinib is a kinase inhibitor drug recently approved for the treatment of alopecia areata (AA) in both adults and adolescents based on a single, combined Phase 2b/3 study. Various QD doses with and without a loading dose have been evaluated in the pivotal Phase 2b/3 study.
Yeamin Huh +5 more
wiley +1 more source
Treatments for alopecia areata: a network meta‐analysis. [PDF]
, 2023 Background Alopecia areata is an autoimmune disease leading to nonscarring hair loss on the scalp or body. There are different treatments including immunosuppressants, hair growth stimulants, and contact immunotherapy.
Correa Pérez, Andrea +4 more
core +1 more source
International Journal of Dermatology, Volume 64, Issue 6, Page 1013-1020, June 2025.ABSTRACT Despite increasing attention regarding skin diseases in individuals with skin of color (SoC), there remains a significant gap in understanding and identifying inflammatory nail disorders in this population. This systematic review aims to synthesize the clinical and onychoscopic features of inflammatory nail disorders in patients with SoC ...
Lea Tordjman +3 more
wiley +1 more source
Computer-guided concentration-controlled trials in autoimmune disorders [PDF]
, 1993 A randomized concentration-controlled clinical trial (RCCCT) is an alternate experimental design to the standard dose-controlled study. In a RCCCT, patients are randomly assigned to predefined plasma or blood drug concentration ranges (low, medium, and ...
Doyle, H +7 more
core +1 more source
EFFICACY OF METHOTREXATE ALONE OR WITH LOW-DOSE PREDNISONE IN ALOPECIA AREATA TOTALIS
Biological and Clinical Sciences Research Journal, 2023 This study aimed to evaluate the efficacy of methotrexate alone or in combination with low-dose prednisone in treating alopecia areata totalis. A randomized controlled trial was conducted among 100 patients diagnosed with alopecia areata totalis ...
H. Mughal +5 more
semanticscholar +1 more source
Acne exacerbation after tofacitinib treatment for alopecia areata
Dermatology Reports, 2021 The major discovery of the novel therapeutic Janus kinase (JAK) inhibitors has been implicated in several dermatological diseases. Recently, studies have shown the efficacy and encouraging results of oral JAK inhibitors as a treatment for alopecia areata
Sawsan Alharthi +2 more
doaj +1 more source
Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 6, Page 1152-1162, June 2025.ALLEGRO‐LT (NCT04006457) is an open‐label, phase 3 study investigating the long‐term safety and efficacy of ritlecitinib in patients with alopecia areata (AA). In this analysis in 449 de novo patients with AA and ≥25% scalp hair loss, ritlecitinib demonstrated clinical efficacy and had an acceptable safety profile through Month 24.
C. Tziotzios +11 more
wiley +1 more source
Indian Journal of Rheumatology, 2019 Azathioprine, an analog of mercaptopurine, is used for various inflammatory/autoimmune diseases in diverse fields such as rheumatology, ophthalmology, gastroenterology, and neurology.
Debashish Mishra +4 more
doaj +1 more source
Dermatologica Sinica, 2022 Background: Diphenylcyclopropenone (DPCP) is a topical contact allergen used for contact immunotherapy in alopecia areata (AA). Objectives: We aimed to evaluate the treatment effectiveness and prognostic factors in Taiwanese patients with AA treated with
Chang-Ming Huang, Tsen-Fang Tsai
doaj +1 more source
Exomic sequencing of immune-related genes reveals novel candidate variants associated with alopecia universalis. [PDF]
PLoS ONE, 2013 Alopecia areata (AA) is a common autoimmune disorder mostly presented as round patches of hair loss and subclassified into alopecia totalis/alopecia universalis (AT/AU) based on the area of alopecia.
Seungbok Lee +9 more
doaj +1 more source